advanced search

<< Back To Home

Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis — Beijing, China, 2014–2016

Tuesday, 30th of January 2018

Introduction of Inactivated Poliovirus Vaccine and Impact on Vaccine-Associated Paralytic Poliomyelitis — Beijing, China, 2014–2016

https://www.cdc.gov/mmwr/volumes/66/wr/mm6649a4.htm

Morbidity and Mortality Weekly Report, December 15, 2017 / 66(49);1357–1361

Dan Zhao, MD¹; Rui Ma, MD¹; Tao Zhou, MD¹; Fan Yang, MD¹; Jin Wu, MD²; Hao Sun³; Fang Liu, MD⁴; Li Lu, MD¹; Xiaomei Li¹; Shuyan Zuo, MD⁵; Wei Yao⁶; Jian Yin⁶ (View author affiliations)

Summary

What is already known about this topic?

Since 2014, the World Health Organization has recommended that all countries using oral poliovirus vaccine (OPV) introduce at least 1 dose of inactivated polio vaccine (IPV) into routine immunization programs. However, the evaluation of IPV introduction after this global recommendation was limited, including the impact that IPV introduction might have on the existing immunization program. Beijing Municipal Authority implemented the first province-wide IPV introduction in China on December 5, 2014 with a sequential IPV/OPV poliovirus vaccination schedule.

What is added by this report?

Two years after introduction of the sequential IPV/OPV vaccination schedule in Beijing, a postintroduction evaluation was conducted. The sequential schedule was successfully introduced into the public-sector Expanded Program on Immunization system and was well accepted by parents and providers. Compared with the year preceding IPV introduction, polio vaccination coverage remained high, no adverse effect on coverage with other vaccines occurred, and no cases of vaccine-associated paralytic poliomyelitis have been identified.

What are the implications for public health practice?

Comprehensive IPV introduction plans not only ensure a smooth transition to a new vaccine schedule, but can also help improve the current routine immunization system. Good planning and preparation can lead to high coverage with a new vaccine without negative impact on coverage with other vaccines. The experience in Beijing helped contribute to expansion of IPV use nationwide in China, and can also aid IPV introductions in other OPV-using countries.